The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation

Overview of attention for article published in BMC Cancer, March 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

twitter: 25 X users

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 36 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 39 X posts from 25 X users, with an upper bound of 228,256 followers.

RT @nicb_dcu: NICB @DCUFSH research with partner @UCD_SBBS funded by @TheMaterFoundat identifies new target in prostate cancer https://t.co…

Reply Repost Favourite

NICB @DCUFSH research with partners @UCD_Conway @UW @UWArtSci @UWMedicine identifies a new target in prostate cancer https://t.co/SQ7A2tU4X6 https://t.co/6MqfLKv5hD

Reply Repost Favourite

RT @nicb_dcu: NICB @DCUFSH research with partner @UCD_SBBS funded by @TheMaterFoundat identifies new target in prostate cancer https://t.co…

Reply Repost Favourite

https://t.co/BP4A0VUE8P

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 35 additional X posts.